Clinical Trial: Biomarkers and Event Patterns of Vascular Disease in Hemodialysis

U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07170761) titled 'Biomarkers and Event Patterns of Vascular Disease in Hemodialysis' on Aug. 27.

Brief Summary: Parathyroid hormone (PTH) remains the central biomarker to classify CKD-metabolic bone disease (CKD-MBD) in hemodialysis patients. While PTH-values are known to be associated with adverse outcomes, interventional studies have failed to show a benefit of pharmacological modulation of PTH levels on hard clinical outcomes. To address this gap, the investigators explored alternative markers of bone metabolism, vascular calcification and inflammation in association to prospective event patterns.

Study Start Date: Oct. 15, 2022

Study Type: OBS...